Ovidrel: Clinical Trials

7 trials of Ovidrel, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated, 2 unknown, 1 withdrawn. 7 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 27Completed 2, Terminated 2, Unknown 2, Withdrawn 1
Phase 31Completed 1

Follow Ovidrel: new trials by email Literature Review of Ovidrel trials Research Report on Ovidrel

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole
Progesterone Vaginal Gel 8%, Letrozole Oral Tablet, pelvic ultrasound - Polycystic Ovary Syndrome
Phase 2 / Phase 3CompletedEastern Virginia Medical School522012-07-062018-02-26
Safety Study of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1
NTx 265 - Traumatic Brain Injury
Phase 2UnknownUniversity of Calgary102010-11-012010-11-11
To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation
Luveris - Infertility
Phase 2UnknownPeking University Third Hospital1502009-12-012009-12-10
Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
human chorionic gonadotropin (hCG), then epoetin alfa (EPO), Saline Placebo - Stroke
Phase 2TerminatedStem Cell Therapeutics Corp.962009-08-012011-11-29
REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
NTx™-265: rhCG, then rEPO, Saline Placebo - Stroke
Phase 2WithdrawnStem Cell Therapeutics Corp.302009-08-012011-09-05
REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
NTx™-265: rhCG, then rEPO, Saline placebo - Stroke
Phase 2TerminatedStem Cell Therapeutics Corp.1342008-03-012009-08-12
Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)
AS900672-Enriched 50 microgram (mcg), AS900672-Enriched 100 mcg, AS900672-Enriched 150 mcg - Infertility
Phase 2CompletedMerck KGaA, Darmstadt, Germany5202007-01-012014-02-13

Conditions studied

Stroke (3)  ·  Infertility (2)  ·  Brain Injuries, Traumatic (1)  ·  Polycystic Ovary Syndrome (1)

Sponsors

Stem Cell Therapeutics Corp. (3)  ·  Eastern Virginia Medical School (1)  ·  Merck KGaA, Darmstadt, Germany (1)  ·  Peking University Third Hospital (1)  ·  University of Calgary (1)

Countries

United States (4)  ·  Canada (3)  ·  India (2)  ·  China (1)

Top investigators

Michael D Hill, MD (2)  ·  Steven C Cramer, MD (2)  ·  David A Zygun, MD, MSc (1)  ·  Jie Qiao, MD, PhD (1)  ·  Laurel A Stadtmauer, MD, PhD (1)  ·  Steven C Cramer, MD, MMSc (1)  ·  Zourab Bebia, MD (1)

Results publications

PMID 24588854